TY  - JOUR
T1  - From DNA to Doses: How Pharmacogenomics Transforms Depression Care in Community Pharmacy
A1  - Momin Shabana
A1  - Nusrath Fatima
A1  - T. Kusuma Teja
A1  - Umar Zeshan
JF  - Archives of Pharmacy Practice
JO  - Arch Pharm Pract
SN  - 2320-5210
Y1  - 2025
VL  - 16
IS  - 2
DO  - 10.51847/Si19CmLJuz
SP  - 12
EP  - 18
N2  - Pharmacogenomic testing can identify these genetic variations, allowing healthcare providers to adjust drug selection and dosage accordingly. These tests typically involve a simple cheek swab or saliva sample, which is then analysed to identify specific genetic variations that affect drug metabolism and response. Cytochrome P450 (CYP450) enzyme is responsible for the metabolism of many antidepressants. CYP2D6 and CYP2C19 may cause variations in how drugs are metabolized. A neurotransmitter involved in mood modulation, the serotonin transporter gene (SLC6A4), affects serotonin reuptake. Val66Met, a gene for the brain-derived neurotrophic factor (BDNF), has been connected to variations in how people react to antidepressants. Effective implementation of pharmacogenomics in clinical practice requires supportive policies that address issues such as reimbursement, education, and privacy. Among the pharmacist's duties are analyzing genetic information, working with medical professionals, offering patient counseling, and incorporating pharmacogenomics into the administration of drug therapy. Patients with severe depressive disorders had much better results when a combinatorial pharmacogenomic test was used to detect and target those with expected gene-drug interactions. Utilizing a structured data framework of genetic, phenotypic, and environmental characteristics, personalized medicine should offer the healthcare system practical methods to maximize the efficacy of certain treatments. 
UR  - https://archivepp.com/article/from-dna-to-doses-how-pharmacogenomics-transforms-depression-care-in-community-pharmacy-vubijynhnqfqcmx
ER  -